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Anthology of publications and presentations associated with this thesis 
 
Papers Published 
Sheerin NJ, Newton PJ, Macdonald PS, Leung DY, Sibbritt D, Spicer ST, Johnson K, Krum H, 
Davidson PM. Worsening renal function in heart failure: the need for a consensus definition. 
Int J Cardiol. 2014 Jul 1; 174(3):484-91. doi: 10.1016/j.ijcard.2014.04.162. Epub 2014 Apr 21. 
PubMed PMID: 24801076. (Impact factor 6.18) 
Deek H, Newton P, Sheerin N, Noureddine S, Davidson PM. Contrast media induced 
nephropathy: A literature review of the available evidence and recommendations for practice. 
Aust Crit Care. 2014 Jan 22. pii: S1036-7314(13)00266-X. doi: 10.1016/j.aucc.2013.12.002. 
[Epub ahead of print] PubMed PMID: 24461960. (Impact factor 1.27) 
Shehab S, Luckett T, Phillips JL, Currow DC, Newton PJ, Thompson SC, Sheerin NJ, Allida SM, Di 
Salvo D, Inglis SC, Davidson PM. (In preparation) Chart reviews: an overlooked and important 
data source and recommendations for methodological standards. 
 
Conferences/presentations 
Sheerin NJ, Newton PJ, Macdonald PS, Leung DY, Spicer ST, Johnson K, Krum H, Davidson PM.  
Would acute kidney injury definitional concordance across generalist & specialist health 
professional groups improve patient outcomes? Poster presentation at the Guidelines 






Certificate of original authorship  
 
I certify that the work in this thesis has not previously been submitted for a degree nor has it 
been submitted as part of requirements for a degree except as fully acknowledged within the 
text. 
I also certify that the thesis has been written by me. Any help that I have received in my 
research work and the preparation of the thesis itself has been acknowledged. In addition, I 
certify that all information sources and literature used are indicated in the thesis. 
Signature of Student: 
Noella J Sheerin 
Date: 






Table of Contents 
 
Acknowledgement .................................................................................................................................. i 
Anthology of publications and presentations associated with this thesis .........................................iii 
Certificate of original authorship ......................................................................................................... iv 
Table of Contents ................................................................................................................................... v 
List of Tables .......................................................................................................................................... xii 
List of Figures ........................................................................................................................................ xiv 
List of Appendices ................................................................................................................................. xv 
Abstract ................................................................................................................................................. xvi 
Abbreviations...................................................................................................................................... xviii 
Glossary ................................................................................................................................................ xxii 
Chapter 1 Introduction .......................................................................................................................... 1 
1.1 Introduction ............................................................................................................................... 2 
1.2 Background ................................................................................................................................ 2 
1.2.1 Cardiorenal syndrome .......................................................................................................... 2 
1.2.2 Cardio-renal research challenges ........................................................................................ 4 
1.3 Context ....................................................................................................................................... 5 
1.3.1 Chronic heart failure ............................................................................................................. 5 
1.3.2 Acute decompensated heart failure.................................................................................... 6 
1.3.3 Global heart failure burden .................................................................................................. 6 
1.3.4 Individual heart failure burden ............................................................................................ 7 
1.3.5 Kidney disease ....................................................................................................................... 8 
1.3.6 Chronic kidney disease ......................................................................................................... 9 
1.3.7 Acute kidney injury ............................................................................................................. 10 
1.3.8 Chronic kidney disease burden .......................................................................................... 11 





1.3.10 Renal impairment and worsening renal function in heart failure .............................. 12 
1.3.11 Worsening renal function in heart failure burden ....................................................... 13 
1.4 Purpose .................................................................................................................................... 14 
1.4.1 Study aims ........................................................................................................................... 14 
1.4.2 Study objectives .................................................................................................................. 15 
1.5 Significance, Scope & Definitions ........................................................................................... 15 
1.5.1 Significance .......................................................................................................................... 15 
1.5.2 Scope ................................................................................................................................... 17 
1.5.3 Definitions ........................................................................................................................... 18 
1.6 Thesis Outline .......................................................................................................................... 19 
1.7 References ............................................................................................................................... 21 
Chapter 2 Literature Review ................................................................................................................ 28 
2.1 Introduction ............................................................................................................................. 29 
2.2 Literature review ..................................................................................................................... 29 
2.2.1 Search strategy.................................................................................................................... 30 
2.3 Clinical Practice Guidelines ..................................................................................................... 41 
2.3.1 Background ......................................................................................................................... 41 
2.3.2 Heart failure guidelines and renal function ...................................................................... 41 
2.3.3 European Society of Cardiology Heart Failure Guidelines ............................................... 42 
2.3.4 American College of Cardiology Foundation & American Heart Association HF 
Guidelines ......................................................................................................................................... 43 
2.4 Definitions ................................................................................................................................ 44 
2.4.1 Chronic kidney disease ....................................................................................................... 48 
2.4.2 Acute kidney injury ............................................................................................................. 49 
2.4.3 Defining renal dysfunction in heart failure – the evidence ............................................. 51 
2.5 Biomarkers ............................................................................................................................... 53 





2.6 Estimated glomerular filtration rate (eGFR) equations ........................................................ 55 
2.7 Outcomes................................................................................................................................. 57 
2.8 Demographics.......................................................................................................................... 59 
2.8.1 Chronic kidney disease/ renal impairment in hospitalised heart failure ........................ 59 
2.8.2 Chronic kidney disease in heart failure: the community setting ..................................... 60 
2.8.3 Worsening renal function in hospitalised heart failure ................................................... 62 
2.9 Prevalence ............................................................................................................................... 65 
2.9.1 Acute worsening renal function in hospitalised heart failure ......................................... 65 
2.9.2 Chronic kidney disease in hospitalised heart failure ........................................................ 65 
2.9.3 Chronic kidney disease in community-managed heart failure ........................................ 66 
2.10 Predictors of worsening of renal function in hospitalised heart failure.............................. 66 
2.11 Summary .................................................................................................................................. 68 
2.12 References ............................................................................................................................... 69 
Chapter 3 Methodology ....................................................................................................................... 77 
3.1 Introduction ............................................................................................................................. 78 
3.2 Rationale for the study design ............................................................................................... 78 
3.3 Chart audit as the research methodology ............................................................................. 78 
3.3.1 Introduction ........................................................................................................................ 78 
3.3.2 Limitations of the chart audit ............................................................................................. 79 
3.3.3 Pilot study ............................................................................................................................ 79 
3.4 Study hypotheses .................................................................................................................... 80 
3.5 Participants .............................................................................................................................. 81 
3.5.1 Setting .................................................................................................................................. 81 
3.5.2 Sample size .......................................................................................................................... 82 
3.5.3 Cohort sampling .................................................................................................................. 82 
3.5.4 Selection of the cohort ....................................................................................................... 83 





3.6 Definitions ................................................................................................................................ 84 
3.6.1 Heart failure ........................................................................................................................ 85 
3.6.2 Chronic kidney disease and renal impairment ................................................................. 85 
3.6.3 Worsening renal function................................................................................................... 87 
1.1.1 Blood pressure .................................................................................................................... 88 
3.7 Data collection ......................................................................................................................... 88 
3.7.1 Case record form (CRF) ....................................................................................................... 89 
3.8 Study Measurements .............................................................................................................. 89 
3.8.1 Demographics – participant details ................................................................................... 89 
3.8.2 Admission examination ...................................................................................................... 90 
3.8.3 Aetiology of heart failure, management and co-morbidity burden ............................... 91 
3.8.4 Medical history.................................................................................................................... 92 
3.8.5 Index event management .................................................................................................. 92 
3.8.6 Complications ...................................................................................................................... 93 
3.8.7 Procedures .......................................................................................................................... 94 
3.8.8 Discharge planning ............................................................................................................. 94 
3.8.9 Fluid status on discharge .................................................................................................... 95 
3.8.10 Participant discharge destination status ...................................................................... 95 
3.8.11 Medications .................................................................................................................... 95 
3.8.12 Biochemistry and haematology results ........................................................................ 96 
3.8.13 Haemodynamic clinical series ....................................................................................... 96 
3.9 Instruments and reliability...................................................................................................... 96 
3.9.1 Modification of Diet in Renal Disease (MDRD) eGFR formula......................................... 96 
3.9.2 Acute kidney injury network (modified) acute kidney injury metric .............................. 97 
3.9.3 Haemodynamic measures ................................................................................................. 97 
3.10 Study outcome measures ....................................................................................................... 97 





3.10.2 Secondary endpoints...................................................................................................... 98 
3.11 Data analysis ............................................................................................................................ 98 
3.11.1 Data checking ................................................................................................................ 100 
3.11.2 Descriptive analyses ..................................................................................................... 100 
3.11.3 Recoding and formulation of new variables .............................................................. 100 
3.11.4 Survival analysis ............................................................................................................ 101 
3.11.5 Regression modelling ................................................................................................... 102 
3.12 Ethics procedures .................................................................................................................. 102 
3.12.1 Informed consent ......................................................................................................... 102 
3.12.2 Data management ........................................................................................................ 103 
3.12.3 Governance ................................................................................................................... 103 
3.13 Conclusions ............................................................................................................................ 103 
3.14 References ............................................................................................................................. 104 
Chapter 4 Results ................................................................................................................................ 108 
4.1 Introduction ........................................................................................................................... 109 
4.2 Participant recruitment ........................................................................................................ 111 
4.3 Baseline cohort characteristics stratified by in-hospital worsening renal function defined 
as acute kidney injury ........................................................................................................................ 112 
4.4 Incidence of acute kidney injury .......................................................................................... 114 
4.5 Primary outcome for AKI by the composite endpoint all-cause mortality or major acute 
cardiovascular event (MACE) ............................................................................................................ 114 
4.5.1 Kaplan-Meier survival analysis for AKI (WRF_72) status and the composite outcome 
all-cause mortality and MACE ....................................................................................................... 114 
4.6 Secondary outcomes for acute kidney injury ..................................................................... 116 
4.7 Predictors for acute kidney injury ........................................................................................ 117 
4.7.1 Introduction binary logistic regression modelling for predictors of AKI ....................... 117 
4.7.2 Regression modelling results for predictors of AKI ........................................................ 118 





4.8 Characterisation of renal dysfunction in hospitalised heart failure patients ................... 120 
4.8.1 Prevalence of renal impairment, chronic kidney disease and severity by gender ...... 120 
4.8.2 Percent acute kidney injury (AKI) for confirmed CKD group and cohort ...................... 122 
4.8.3 Age, gender and acute kidney injury ............................................................................... 123 
4.8.4 Cohort comorbidities and acute kidney injury (AKI) group ........................................... 125 
4.8.5 Admission haemoglobin by gender and AKI ................................................................... 128 
4.8.6 Admission medication management by AKI group ........................................................ 129 
4.8.7 Beta Blocker medication by AKI (WRF_72) ..................................................................... 130 
4.8.8 Nitrate medications and acute kidney injury .................................................................. 131 
4.8.9 Other vasodilator medication on admission and acute kidney injury .......................... 132 
4.8.10 Maximum intravenous diuretics daily dose and AKI status ...................................... 132 
4.8.11 Renal impairment status and the composite outcome all-cause mortality and MACE
 133 
4.8.12 Chronic kidney disease (CKD) status and the composite outcome all-cause mortality 
and MACE ....................................................................................................................................... 134 
4.8.13 Renal impairment and chronic kidney disease secondary outcomes at 12-months 
follow-up 135 
4.8.14 Chronic kidney disease and secondary outcomes ..................................................... 136 
4.9 Conclusions ............................................................................................................................ 136 
4.10 References ............................................................................................................................. 138 
Chapter 5 Discussion .......................................................................................................................... 139 
5.1 Introduction ........................................................................................................................... 140 
5.2 Incidence of acute kidney injury .......................................................................................... 142 
5.2.1 Definitions and acute kidney injury in heart failure ....................................................... 142 
5.2.2 ReFinH with the context of published literature ............................................................ 143 
5.3 Prevalence of renal impairment .......................................................................................... 144 
5.4 Chronic kidney disease prevalence ...................................................................................... 146 





5.6 Predictors for the development of AKI in the study cohort ............................................... 149 
5.6.1 Chronic kidney disease history as a predictor of AKI ..................................................... 150 
5.6.2 Diabetes mellitus as a predictor of AKI ........................................................................... 151 
5.7 Survival analysis acute kidney injury .................................................................................... 152 
5.8 Secondary endpoints and acute kidney injury .................................................................... 153 
5.9 Implications ........................................................................................................................... 154 
5.10 Summary ................................................................................................................................ 155 
5.10.1 Strengths and weakness of the study design ............................................................. 155 
5.11 Conclusion ............................................................................................................................. 156 
5.12 References ............................................................................................................................. 157 
Chapter 6 Conclusion ......................................................................................................................... 161 
6.1 Introduction ........................................................................................................................... 162 
6.2 Policy ...................................................................................................................................... 164 
6.2.1 The Australian context ..................................................................................................... 164 
6.2.2 Development processes ................................................................................................... 166 
6.2.3 Cardio-renal heart failure policy options ........................................................................ 167 
6.3 Practice .................................................................................................................................. 168 
6.3.1 Why we do what we do ................................................................................................... 168 
6.3.2 ReFinH results and practice implications ........................................................................ 168 
6.4 Education ............................................................................................................................... 169 
6.5 Research................................................................................................................................. 171 
6.6 Conclusion ............................................................................................................................. 173 








List of Tables 
Table 1.1 Cardio-renal syndrome subtypes ...................................................................................4 
Table 1.2 Chronic kidney disease definition and stages ................................................................9 
Table 1.3 Acute Kidney Injury definition and stages: KDIGO 2012 ............................................. 10 
Table 1.4 ReFinH acute kidney injury definition ......................................................................... 15 
Table 1.5 Key heart failure definitions ........................................................................................ 18 
Table 1.6 Key cardio-renal definitions ........................................................................................ 18 
Table 1.7 Key renal definitions .................................................................................................... 19 
Table 2.1 Integrative review process for renal dysfunction in heart failure .............................. 30 
Table 2.2 Medline (Ovid) search strategy and results ................................................................ 31 
Table 2.3 Summary: key references for the literature review renal function in heart failure ... 33 
Table 2.4 Kidney function definitions ......................................................................................... 45 
Table 2.5 Creatinine-based eGFR prediction equations ............................................................. 56 
Table 3.1 Cohort - Heart Failure Principal Discharge Diagnosis ICD-10-AM Codes .................... 83 
Table 3.2 Study inclusion and exclusion criteria ......................................................................... 84 
Table 3.3 Chronic kidney disease stages categorised by glomerular filtration rate ................... 86 
Table 3.4 Case record form (CRF) section headings ................................................................... 89 
Table 3.5 Case report form: demographic & medical administration details ............................ 90 
Table 3.6 Index admission clinical examination variables .......................................................... 91 
Table 3.7 Heart failure aetiology ................................................................................................ 92 
Table 3.8 Medical history: comorbidities.................................................................................... 92 
Table 3.9 Index admission clinical management options ........................................................... 93 
Table 3.10 Index admission complications variable list .............................................................. 94 
Table 3.11 Coronary angiography status, management and result variables ............................ 94 
Table 3.12 Discharge planning variables ..................................................................................... 95 
Table 3.13 Discharge fluid overload status variables ................................................................. 95 
Table 3.14 Participant discharge destination variables .............................................................. 95 
Table 3.15 Key study variables: type........................................................................................... 99 
Table 4.1 Baseline characteristics for cohort stratified by worsening renal function .............. 113 
Table 4.2 Statistic for composite outcome by AKI (WRF_72) ................................................... 115 
Table 4.3 Composite events by AKI (WRF_72) .......................................................................... 116 
Table 4.4 Summary secondary endpoints for AKI group at 12-month follow-up ..................... 117 
Table 4.5 Model summary ........................................................................................................ 118 





Table 4.7 Regression analysis results for predictors of AKI ...................................................... 119 
Table 4.8 Admission chronic kidney disease stage by gender .................................................. 121 
Table 4.9 Chronic kidney disease by AKI (WRF_72) .................................................................. 123 
Table 4.10 Age group and acute kidney injury split for gender ................................................ 123 
Table 4.11 Age groups by gender ............................................................................................. 125 
Table 4.12 AKI by Cerebrovascular disease (CVD) .................................................................... 126 
Table 4.13 AKI by Ischaemic heart disease (IHD) ...................................................................... 127 
Table 4.14 AKI by chronic kidney disease (CKD) ....................................................................... 127 
Table 4.15 AKI by diabetes mellitus .......................................................................................... 128 
Table 4.16 AKI by haemoglobin (Hb) and gender ..................................................................... 129 
Table 4.17 AKI by ß-blockers medication on admission ........................................................... 131 
Table 4.18 AKI by Nitrate medication on admission ................................................................. 131 
Table 4.19 AKI by Other vasodilator medications ..................................................................... 132 
Table 4.20 Secondary outcomes – renal impairment ............................................................... 135 
Table 4.21 Secondary outcomes – chronic kidney disease ....................................................... 136 







List of Figures 
Figure 2.1 Literature review database search results ................................................................. 31 
Figure 3.1 South Western Sydney Local Health Network Projected Population Growth 2011-
2026 ............................................................................................................................................ 82 
Figure 4.1 Cohort recruitment process ..................................................................................... 111 
Figure 4.2 Kaplan-Meier survival curve acute kidney injury group status ................................ 115 
Figure 4.3 Renal impairment count for the cohort by gender and severity ............................. 120 
Figure 4.4 Percent acute kidney injury by chronic kidney disease and cohort......................... 122 
Figure 4.5 Cohort by age group, gender and acute kidney injury ............................................ 124 
Figure 4.6 Prevalence of comorbidities by AKI status............................................................... 125 
Figure 4.7 Admission medications by percent for AKI group ................................................... 130 
Figure 4.8 Kaplan-Meier survival analysis for renal impairment .............................................. 133 
Figure 4.9 Kaplan-Meier survival analysis for confirmed chronic kidney disease .................... 134 
Figure 6.1 Knowledge into policy, practice, education and research ....................................... 166 







List of Appendices 
Appendix 1 Publication International Journal of Cardiology .................................................... 178 








Renal dysfunction is strongly associated with adverse health outcomes in chronic heart failure. 
The term cardio-renal syndrome has been proposed to describe the theoretical models 
developed to explain the pathophysiological mechanisms underpinning the condition and 
many observational studies undertaken to characterise and identify risk factors and morbidity 
and mortality outcomes. There is evidence baseline glomerular filtration rate is a stronger 
predictor of mortality in patients with Heart Failure than left ventricular ejection fraction or 
NYHA functional class. However, the ambiguity surrounding definitions and nomenclature for 
renal dysfunction in heart failure has impeded progress for a clearly defined risk profile and 
characterization for heart failure patients with renal impairment, chronic kidney disease, 
worsening renal function, or acute kidney injury. The focus of this study was to characterize an 
Australian cohort of hospitalised heart failure patient who developed acute kidney injury, and 
investigate this relationship in terms of morbidity and mortality at 12-months follow-up. A 
secondary purpose was to determine the prevalence of confirmed chronic kidney disease and 
renal impairment in the cohort and their outcomes. The results highlight the prevalence of 
Renal Insufficiency and Chronic Kidney Disease, 59% and 52% respectively. Acute kidney injury 
occurred in 1 in 4 patients when diagnosed using a modified AKIN definition. Characterization 
of HF patients with any type of renal abnormality revealed a history of multiple comorbidities 
where concurrent diabetes exposed hospitalised HF patients to an increased risk of AKI. From 
an original sample of 265 admissions, 166 had data available for the 12-month follow-up 
morbidity and survival analysis. The reduced sample size limited the study power, such that 
only renal impairment was trending towards significance. The Kaplan-Meier survival 
distributions for acute kidney injury and renal impairment at 12-months follow-up was not 
statistically significant, log-rank p=0.4714 and p=0.0579 respectively. The findings confirm the 
high incidence and prevalence of renal dysfunction in hospitalised heart failure patients and 





community monitoring of renal function and the need for definitional and nomenclature 
consensus. A move towards improved monitoring and a standardised taxonomy would assist 
with differentiating renal dysfunction types and may lead to better risk stratification of HF 








Abbreviation Full term 
ABS Australian Bureau of Statistics 
ACCF American College of Cardiology Foundation 
ACE Angiotensin-converting enzyme 
ACE -I Angiotensin-converting enzyme - Inhibitor 
ACR Albumin Creatinine Ratio 
ADHF Acute Decompensated Heart Failure 
AHA American Heart Association 
AKI Acute Kidney Injury 
AKIN Acute Kidney Injury Network 
ARB Angiotensin II Receptor Blocker 
BiPAP Biphasic intermittent positive airway pressure 
BMI Body mass index  
BSA Body surface area 
CAD Coronary artery disease 
CGE Cockcroft-Gault Equation 
CHF Chronic Heart Failure or Congestive Heart Failure 
CI Confidence interval 
CKD Chronic Kidney Disease 
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration  
CKMB Creatine kinase myocardial band isoenzyme  





Abbreviation Full term 
CPAP Continuous positive airway pressure 
CPGs Clinical practice guidelines 
CrCl Creatinine clearance  
CRF Clinical or case report form 
CRS Cardiorenal syndrome 
CVD Cerebrovascular disease 
DBP Diastolic blood pressure 
ECS European Society of Cardiology 
ED Emergency Department 
eGFR Estimated Glomerular Filtration Rate 
EPR Electronic patient record 
GFR Glomerular Filtration Rate 
GTN Glyceryl Trinitrate 
HREC Human Research Ethics Committee 
HF Heart Failure 
HFpEF Heart Failure preserved ejection fraction 
HFrEF Heart failure reduced ejection fraction 
HHF Hospitalised heart failure 




International Classification of Diseases 10th revision Australian 
Modification based on the World Health Organization’s 
internationally accepted classification of death and disease 





Abbreviation Full term 
IQR Inter quartile range 
IV Intravenous  
IVI Intravenous infusion 
JVP Jugular venous pressure 
KDIGO Kidney Disease Improving Global Outcomes 
KDOQI Kidney Disease Outcomes Quality Initiative 
KIM-1 Kidney injury molecule-1  
LOS Length of stay 
LVF Left ventricular function 
MACE Major acute cardiac event 
MCV Mean cell volume 
MDRD Modification of Diet in Renal Disease 
MRAs Mineralocorticoid receptor antagonists 
NGAL neutrophil gelatinase-associated lipocalin 
NKF National Kidney Foundation 
Non-STEMI Non S-T Elevation Myocardial Infarct 
NSAIDs Non-steroidal anti-inflammatory drugs  
NYHA New York Heart Association 
OR Odds Ratio 
RCT Randomised Control Trials 
RD Renal dysfunction 
RDW Red cell distribution width 





Abbreviation Full term 
RI Renal Impairment/ Insufficiency 
RIFLE Risk-Injury-Failure-Loss-Endstage renal disease 
RR Relative Risk 
SaO2 Arterial oxygen saturation 
SBP Systolic blood pressure 
SCr Serum creatinine 
SD Standard deviation  
SIEFA Socio-economic Indexes for Areas 
sMDRD Simplified Modification of Diet in Renal Disease  
SPSS Statistical Package for Social Sciences  
STEMI S-T Elevation Myocardial Infarct 
SWSLHN South Western Sydney Local Health Network 
UTS University of Technology 
VAD Ventricle assist device 









Acute heart failure De novo acute heart failure or decompensated chronic heart 
failure characterized by signs of pulmonary congestion, 
including pulmonary oedema  
Acute kidney injury AKI is a syndrome characterised by the rapid loss of the 
kidney’s excretory function which is typically diagnosed by an 
significant increase in serum creatinine 
Body mass index  A measure of an adult's weight (body mass) relative to height 
used to assess the extent of weight deficit or excess. BMI uses 
a simple calculation based on the ratio of someone’s height 
and weight (BMI = kg/m2).  
Cardiovascular disease 
 
A disease affecting the heart or blood vessels. Cardiovascular 
diseases include arteriosclerosis, coronary artery disease, 
heart valve disease, arrhythmia, heart failure, hypertension, 
orthostatic hypotension, shock, endocarditis, diseases of the 
aorta and its branches, disorders of the peripheral vascular 
system, and congenital heart disease 
Chronic condition A health condition that is long term; has a pattern of 
recurrence, or deterioration; has a poor prognosis and 
produces consequences, or sequelae that impact on the 
individual's quality of life 
Chronic heart failure  A complex clinical syndrome with typical symptoms (e.g. 
shortness of breath, fatigue) that can occur at rest or on 
effort, and is characterised by objective evidence of an 
underlying structural abnormality of cardiac dysfunction that 
impairs the ability of the ventricle to fill with or eject blood 
(particularly during physical activity). 
Chronic kidney disease Abnormalities of kidney structure or function, present for 
more than 3 months, with implications for health and 
classified based on cause, GFR category, and albuminuria 
category 







Confidence interval (CI) A statistical term describing a range (interval) of values within 
which we can be ‘confident’ that the true value lies, usually 
because it has a 95% or higher chance of doing so 
Diabetes A disease marked by high blood glucose levels resulting from 
defective insulin production, insulin action or both. The three 
main types of diabetes are type-1 diabetes, type-2 diabetes 
and gestational diabetes. Where a person has a history of 
diabetes; a diagnosis of diabetes. 
Dyspnoea  Difficult or laboured breathing; shortness of breath 
Ejection fraction  Refers to the amount, or percentage, of blood that is pumped 
out of the ventricles with each contraction; the left ventricle 
percentage is most frequently recorded 
Health outcome  A change in the health of an individual, or a group of people 
or a population, which is wholly or partially attributable to an 
intervention or a series of interventions 
Heart failure  Described in physiological terms HF is a syndrome 
characterized by either or both pulmonary and systemic 
venous congestion and/or inadequate peripheral oxygen 
delivery, at rest or during stress, caused by cardiac 
dysfunction. 
Incidence  Refers to the number of individuals who develop a specific 
disease or experience a specific health-related event during a 
particular time period (such as a month or year)  
Length of stay Duration of hospital stay, calculated by subtracting the date 
the patient is admitted from the day of separation. A same-
day patient is allocated a length of stay of 1 day 
Local hospital network LHNs are small groups of local hospitals, or an individual 
hospital, linking services within a region or through specialist 
networks across a state or territory.  






a population or group 
New York Heart Association  
– functional class  
Mainly describes the functional limitations of the patient such 
that Class I – ordinary physical activity does not cause undue 
fatigue, palpitations, dyspnoea and/or angina; Class II - 
ordinary physical activity does cause undue fatigue, 
palpitations, dyspnoea and/or angina; Class – III Less than 
ordinary physical activity cause undue fatigue, palpitations, 
dyspnoea and/or angina; and Class- IV fatigue, palpitations, 
dyspnoea and/or angina occur at rest.  
Orthopnoea  Discomfort or difficulty breathing when lying flat  
Prevalence  Refers to the total number of individuals in a population who 
have a disease or health condition at a specific period of time, 
usually expressed as a percentage of the population 
Principal diagnosis The diagnosis listed in hospital records to describe the 
problem that was chiefly responsible for the patient’s episode 
of care in hospital 
Quality of life A generic term that measures the individual’s perception of 
their life experience. It is a multidimensional concept 
measuring important aspects or domains of a person’s life 
including physical functioning, psychological processes and 
social and economic concerns, as well as spiritual and 
existential aspects.  
Renal impairment Acute or chronic kidney failure also known as ‘renal 
insufficiency’ or ‘renal dysfunction’ It is a medical condition in 
which the kidneys fail to adequately filter waste products 
from the blood.  
Risk Factors  A risk factor is any attribute, characteristic or exposure of an 
individual that increases the likelihood of developing a 
disease or injury 
Stroke Diagnosis for ischaemic: non-haemorrhagic cerebral infarction 






cerebral imaging  
Taxonomy A classification containing domains and subcategories for the 
measurement properties and aspects of measurement 
properties which are the subcategories 
Albuminuria An abnormal excretion rate of albumin (protein) in the urine 
Glomerular filtration rate The amount of ultrafiltrate formed by plasma flowing through 
the glomeruli of the kidney. 
 
